OmniAb, Inc. (OABI) Reports Q4 Loss, Tops Revenue Estimates

Core Viewpoint - OmniAb, Inc. reported a quarterly loss of $0.12 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.13, and improved from a loss of $0.14 per share a year ago, indicating a positive earnings surprise of 7.69% [1] Financial Performance - The company posted revenues of $10.8 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 18.21%, and showing significant growth from $4.82 million in the same quarter last year [2] - Over the last four quarters, OmniAb has surpassed consensus EPS estimates two times and has also topped consensus revenue estimates two times [2] Stock Performance - OmniAb shares have declined approximately 10.5% since the beginning of the year, compared to a decline of 3.5% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $6.16 million, and for the current fiscal year, it is -$0.46 on revenues of $47.55 million [7] Industry Outlook - The Medical - Drugs industry, to which OmniAb belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook as the top 50% of Zacks-ranked industries tend to outperform the bottom 50% by more than 2 to 1 [8]